Home/Filings/4/0001358403-16-000272
4//SEC Filing

BELLICUM PHARMACEUTICALS, INC 4

Accession 0001358403-16-000272

CIK 0001358403operating

Filed

Sep 22, 8:00 PM ET

Accepted

Sep 23, 6:55 PM ET

Size

13.7 KB

Accession

0001358403-16-000272

Insider Transaction Report

Form 4
Period: 2016-09-21
Moseley Ken
Vice President
Transactions
  • Sale

    Common Stock

    2016-09-21$20.04/sh100$2,004344 total
  • Sale

    Common Stock

    2016-09-23$20.10/sh11,700$235,198344 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2016-09-2110040,817 total
    Exercise: $7.47Exp: 2024-11-10Common Stock (100 underlying)
  • Exercise/Conversion

    Common Stock

    2016-09-23$7.47/sh+11,700$87,39912,044 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2016-09-2311,70029,117 total
    Exercise: $7.47Exp: 2024-11-10Common Stock (11,700 underlying)
  • Exercise/Conversion

    Common Stock

    2016-09-21$7.47/sh+100$747444 total
Footnotes (3)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 24, 2015 by the Reporting Person.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F3]25% of the shares subject to the stock option vest and become exercisable on November 11, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.

Issuer

BELLICUM PHARMACEUTICALS, INC

CIK 0001358403

Entity typeoperating

Related Parties

1
  • filerCIK 0001358403

Filing Metadata

Form type
4
Filed
Sep 22, 8:00 PM ET
Accepted
Sep 23, 6:55 PM ET
Size
13.7 KB